Abstract
Drug efflux proteins are widespread amongst microorganisms, including pathogens. They can contribute to both natural insensitivity to antibiotics and to emerging antibiotic resistance and so are potential targets for the development of new antibacterial drugs. The design of such drugs would be greatly facilitated by knowledge of the structures of these transport proteins, which are poorly understood, because of the difficulties of obtaining crystals of quality. We describe a structural genomics approach for the amplified expression, purification and characterisation of prokaryotic drug efflux proteins of the Major Facilitator Superfamily (MFS) of transport proteins from Helicobacter pylori, Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Bacillus subtilis, Brucella melitensis, Campylobacter jejuni, Neisseria meningitides and Streptomyces coelicolor. The H. pylori putative drug resistance protein, HP1092, and the S. aureus QacA proteins are used as detailed examples. This strategy is an important step towards reproducible production of transport proteins for the screening of drug binding and for optimisation of crystallisation conditions to enable subsequent structure determination.
Keywords: Membrane transport, transport protein, drug resistance, antibiotic resistance, multidrug resistance, gene expression, protein production, membrane protein
Current Drug Targets
Title: Microbial Drug Efflux Proteins of the Major Facilitator Superfamily
Volume: 7 Issue: 7
Author(s): Martin K. Pos, Peter J.F. Henderson, Roslyn M. Bill, Melissa H. Brown, Nicholas G. Rutherford, John O'Reilly, Ian T. Paulsen, Ronald A. Skurray, Richard B. Herbert, Kate Langton, Karl Walraven, Patrick Butaye, Massoud Saidijam, Scott Morrison, Johan Meuller, Gerda Szakonyi, Kim E. Bettaney, Alison Ward, Sarah L. Palmer, Christopher J. Hoyle, Zhiqiang Xu, Qinghu Ren and Giulia Benedetti
Affiliation:
Keywords: Membrane transport, transport protein, drug resistance, antibiotic resistance, multidrug resistance, gene expression, protein production, membrane protein
Abstract: Drug efflux proteins are widespread amongst microorganisms, including pathogens. They can contribute to both natural insensitivity to antibiotics and to emerging antibiotic resistance and so are potential targets for the development of new antibacterial drugs. The design of such drugs would be greatly facilitated by knowledge of the structures of these transport proteins, which are poorly understood, because of the difficulties of obtaining crystals of quality. We describe a structural genomics approach for the amplified expression, purification and characterisation of prokaryotic drug efflux proteins of the Major Facilitator Superfamily (MFS) of transport proteins from Helicobacter pylori, Staphylococcus aureus, Escherichia coli, Enterococcus faecalis, Bacillus subtilis, Brucella melitensis, Campylobacter jejuni, Neisseria meningitides and Streptomyces coelicolor. The H. pylori putative drug resistance protein, HP1092, and the S. aureus QacA proteins are used as detailed examples. This strategy is an important step towards reproducible production of transport proteins for the screening of drug binding and for optimisation of crystallisation conditions to enable subsequent structure determination.
Export Options
About this article
Cite this article as:
Pos K. Martin, Henderson J.F. Peter, Bill M. Roslyn, Brown H. Melissa, Rutherford G. Nicholas, O'Reilly John, Paulsen T. Ian, Skurray A. Ronald, Herbert B. Richard, Kate Langton , Karl Walraven , Patrick Butaye , Saidijam Massoud, Scott Morrison , Meuller Johan, Szakonyi Gerda, Bettaney E. Kim, Ward Alison, Palmer L. Sarah, Hoyle J. Christopher, Xu Zhiqiang, Ren Qinghu and Benedetti Giulia, Microbial Drug Efflux Proteins of the Major Facilitator Superfamily, Current Drug Targets 2006; 7 (7) . https://dx.doi.org/10.2174/138945006777709575
DOI https://dx.doi.org/10.2174/138945006777709575 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From Nucleic Acids to Drug Discovery: Nucleobases as Emerging Templates for Drug Candidates
Current Medicinal Chemistry CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders
Mini-Reviews in Medicinal Chemistry Novel Approaches to Target Pancreatic Cancer
Current Cancer Drug Targets Src Family Kinases as Regulators of Angiogenesis: Therapeutic Implications
Current Cancer Therapy Reviews Nanomedicines as Therapeutics in HIV-AIDS
Pharmaceutical Nanotechnology Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Overview of Cantharidin and its Analogues
Current Medicinal Chemistry Anti-metastatic Treatment in Colorectal Cancer: Targeting Signaling Pathways
Current Pharmaceutical Design Involvement of the P2X7 Purinergic Receptor in Inflammation: An Update of Antagonists Series Since 2009 and their Promising Therapeutic Potential
Current Medicinal Chemistry An Overview of the Effect of Weight Loss on Cardiovascular Autonomic Function
Current Diabetes Reviews Status of Programmed Death Ligand 1 (PD-L1) by Immunohistochemistry and Scoring Algorithms
Current Drug Targets Metabolism of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy: A Review of the Literature
Current Drug Metabolism The Effects of Nanoencapsulated Curcumin-Fe3O4 on Proliferation and hTERT Gene Expression in Lung Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Design and Synthesis of 4(1H)-quinolone Derivatives as Autophagy Inducing Agents by Targeting ATG5 Protein
Letters in Drug Design & Discovery Protease-Activated Receptor-2 Antagonists and Agonists
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets Base Excision Repair, the Redox Environment and Therapeutic Implications
Current Molecular Pharmacology Roles of Natural Compounds from Medicinal Plants in Cancer Treatment: Structure and Mode of Action at Molecular Level
Medicinal Chemistry Recent Advances in the Probe Development of Technetium-99m Molecular Imaging Agents
Current Organic Synthesis Nanomulsion as a Carrier for Efficient Delivery of Metformin
Current Drug Delivery